Desktop Site
|
19 Apr 24 | 16:00
|
Close
Equity
SME
Eq Drv
Currency
Commodity
Corporates
Watch List
Get Quote
*
Notices
|
S&P
BSE SENSEX
73,088.33
+599.34
+0.83 %
Corporate Announcement
Security Code
509079
Company
GUFIC BIOSCIENCES LTD.
Exchange Received Time
10/08/2020 18:13:12
Exchange Disseminated Time
10/08/2020 18:13:19
Time Taken
00:00:07
Intimation Under Regulation 30 Of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 |
08/10/20 18:13
This is in reference with the Scheme of Amalgamation of Gufic Biosciences Limited ('the Company') with Gufic Lifesciences Private Limited ('GLPL') and their respective shareholders and creditors, for which 'No Observation Letters' have been received by BSE Limited and National Stock Exchange of India Limited vide their letters dated April 15, 2020.As informed in the Management Report submitted on July 31, 2020 along with the Audited Financial Results of the Company for the quarter and financial year ended March 31, 2020, GLPL has entered into a Loan License Agreement with Hetero Labs Limited ('Hetero') to manufacture and supply Remdesivir Lyophilised Powder for injection (100 mg/vial) on loan license basis to Hetero for its sale in various countries including India. Hetero was the first company in India to launch Remdesivir Lyophilised Powder for injection indicated for emergency use in COVID 19 patients.
Attachment
<< Back
Recently Viewed